Undoubtedly radiotherapy is the treatment of choice for advanced localized breast cancer. In the past, mastectomy alone had produced a high rate of local recurrence and only a 100% five-year survival rate (Cade 1949 ). The addition of postoperative radiotherapy did not alter the longterm prognosis.
Since a significant number of women with totally untreated breast carcinoma will survive five years (22 % in Daland's series, 1927 and 28 % in Philips' series, 1959) , the aim of radiotherapy must be not only to increase the quantity, but also the quality of life by achieving the best possible local control of disease without inflicting undue morbidity.
The policy adopted in Portsmouth since 1960 for the treatment of inoperable carcinoma of the breast has been as follows: (1) Radical radiotherapy to the breast and lymphatic drainage areas, followed by either (2) regular observation in patients showing a good response to radiotherapy, or (3) mastectomy in patients showing a persistent residue or reactivation of the primary tumour, without evidence of disseminated disease. (4) Where surgery is not feasible or if dissemination has occurred then either hormones, hormone ablation or cytotoxics are utilized, as befits the age of the patient and the nature of the disseminated disease.
During the years 1960-69, 267 patients were treated according to this policy by radical cobalt radiotherapy. The technique, still in current use, consisted of 2 parallel opposed glancing fields to the breast area, usually 22 x 11 cm centred 7 cm below the sternal notch, with the medial border 4 cm to the unaffected side of the midline and the lateral border 2 cm behind the posterior axillary fold, with the patient lying on the unaffected side. Both fields were treated daily and wedged as necessary, 6000 rad being delivered over ten weeks to the parasternal area with the maximum dose not exceeding 7000 rad. An additional 3000 rad over eighteen days was delivered to the supraclavicular region on the affected side by a single anterior field. Skin bolus was not used routinely and no additional treatment was given to the axilla.
The side-effects from such treatment were minimal. Erythema and dry desquamation developed during the latter part of the ten-week treatment. No pulmonary complications were Table 1 shows the 267 patients with breast carcinoma who were treated initially by radical radiotherapy between 1960 and 1969. The TNM classification was not used. Thirteen patients had Stage I tumours but were either medically unfit for mastectomy or refused the operation. Twentynine patients had Stage II tumours, 4 were unfit Table 2 shows the number of patients alive and recurrence free at five years. The Stage I and II patients are not under consideration in this paper but of the 24 that survived five years, only 2 had local recurrence, and in both there was associated disseminated disease.
Of the 183 patients in the Stage III group, 138 had radiotherapy alone. Forty survived five years and of these 24 were recurrence free, though 4 patients had required radium needle implant to control persistent residue following radiotherapy and 16 had local recurrence associated with metastatic disease in 11 of the cases. Forty-five Stage III patients had post-irradiation mastectomies, the histological specimens being positive in 40. Twenty-three patients survived five years, 19 were recurrence free and 4 had local recurrence, 2 in association with metastatic disease. Of the Stage III patients 55 % had died before five years with metastatic disease.
Discussion
The crude survival for the Portsmouth series 1960-69 at five years and ten years respectively is shown in Table 3 . For the inoperable Stage III group, the survival is 34% at five years and 19.8 % at ten years. Is the quality and quantity of life in this group any better than in previously reported series? Table 4 compares crude survival rates for Stage III patients.
Bouchard (1965) reported an overall five-year survival of 36% in 60 patients with Stage III disease treated by 250 kV radiation. Using a protracted technique, delivering 6000-8000 rad However, the field arrangement of an opposed anterior-posterior pair treated on alternate days produced fairly marked post-radiation pneumonitis and fibrosis, which was regarded as a justifiable risk by Bouchard, but would be unacceptable by modern therapeutic standards.
Fletcher & Montague (1965) reported on 548 cases of advanced breast carcinoma treated between 1948 and 1963. Using tangential breast fields with anterior and posterior axillary fields, and skin bolus in the cobalt patients, they compared the protracted therapy of Baclasse (1949) , 6000-8000 rad in 12-14 weeks on 250 kV, against the same dose given by cobalt 60 over 8-10 weeks. They observed no significant difference between the two groups in control of local disease but again pneumonitis was a complicating factor in the 250 kV series. They performed mastectomy prior to radiotherapy in the presence of bulky tumours but found that this adversely affected the prognosis in ulcerated lesions. Their five-year survival rate was 32.6 %.
Strickland (1973) reported on 385 cases of advanced breast carcinoma treated by supervoltage 4 MeV radiotherapy, using parallel opposed glancing fields treated daily. He delivered a dose of 6500-7000 rad in 5-6 weeks. The longterm morbidity was considerable with soft-tissue deformity and fibrosis developing between 6 and 24 months after treatment. Twenty per cent of the breasts were plastered to the rib cage and at times inflammatory episodes in the breast simulated local recurrence. Post-radiation rib necrosis was also a complicating factor. Strickland justified such morbidity in that his patients had a good quality oflife and found a scarred breast preferable to an amputated one. They were not subjected to mastectomy at any stage. His Stage III patients had a 36 % five-year survival rate. Guttman (1962) (1965) 25.0 18 43.8 Strickland (1973) 32.0 -of the number of persons alive with no evidence of recurrent disease at the end of a given period of time after treatment, divided by the total number of patients alive at the beginning of that period of time. In the Portsmouth series, this was 23.5% for the whole Stage III group, 17% in the patients treated by radiotherapy alone, and 42% in the patients having post-radiation mastectomy.
Bouchard's recovery rates were almost identical: 18% and 43.8%. Fletcher & Montague achieved a 20% recovery rate and Strickland 32% at five years. Strickland's high-dose radiation technique seems to have given better local control than in other reported series, but not without a very considerable morbidity. It is possible that the Portsmouth recovery rate could well have been improved if the policy had always been strictly adhered to and mastectomy considered in all cases of residual disease. Local recurrence did not follow post-radiation mastectomy and it is likely that most women would prefer the option of a cosmetically acceptable breast with the possibility of mastectomy later if radiotherapy failed, rather than a fibrotic, often painful mass fixed to the chest wall.
The five-year survival rate is very similar in all series and is unlikely to be improved upon by radiotherapy alone. It is governed by factors outside the control of the radiotherapists, namely disseminated disease and the reluctance of patients to present themselves early enough for treatment.
In conclusion, I submit that the technique adopted in Portsmouth for the treatment of advanced carcinoma of the breast achieves a quality and quantity of survival similar to previously reported series, but with very much less morbidity.
